CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		104 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013
OPERATING EXPENSES
General and administrative	$ 433	$ 424	$ 31,920
Research and development	912	556	103,346
Purchased in-process research and development	0	0	34,311
Other	0	0	(375)
Total operating expenses	1,345	980	169,202
Interest and other income, net	(157)	(4)	(14,011)
Loss from continuing operations before taxes	1,188	976	155,191
Income tax benefit	0	0	(1,355)
Loss from continuing operations	1,188	976	153,836
Discontinued operations - net gain on sale of the bone device business, net of taxes of $267	0	0	(2,202)
Net Loss	1,188	976	151,634
Less: Net Loss attributable to the noncontrolling interest	(193)	0	(666)
Net Loss attributable to Capstone Therapeutics Corp. stockholders	$ 995	$ 976	$ 150,968
Per Share Information:
Net loss, basic and diluted, attributable to Capstone Therapeutics Corp. stockholders (in dollars per share)	$ 0.02	$ 0.02
Basic and diluted shares outstanding (in shares)	40,885	40,865